NSE: AJANTPHARM - Ajanta Pharma Limited

Yield per half year: +23.46%
Sector: Healthcare

Company Analysis Ajanta Pharma Limited

Download the report: word Word pdf PDF

1. Summary

Advantages

  • The stock's return over the last year (46.11%) is higher than the sector average (28.88%).
  • The company's current efficiency (ROE=23.47%) is higher than the sector average (ROE=10.72%)

Disadvantages

  • Price (3198.5 β‚Ή) is higher than fair price (740.65 β‚Ή)
  • Dividends (0.7651%) are below the sector average (9.55%).
  • Current debt level 0.7606% has increased over 5 years from 0.0735%.

Similar companies

Divi's Laboratories Limited

Dr. Reddy's Laboratories Limited

Sun Pharmaceutical Industries Limited

Cipla Limited

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

Ajanta Pharma Limited Healthcare Index
7 days 2.4% -2.2% -5%
90 days -8.2% -3.4% -7.7%
1 year 46.1% 28.9% 9%

AJANTPHARM vs Sector: Ajanta Pharma Limited has outperformed the "Healthcare" sector by 17.23% over the past year.

AJANTPHARM vs Market: Ajanta Pharma Limited has outperformed the market by 37.13% over the past year.

Stable price: AJANTPHARM is not significantly more volatile than the rest of the market on "National Stock Exchange Of India" over the last 3 months, with typical variations of +/- 5% per week.

Long period: AJANTPHARM with weekly volatility of 0.8867% over the past year.

3. Summary of the report

3.1. General

P/E: 33.23
P/S: 6.44

3.2. Revenue

EPS 64.77
ROE 23.47%
ROA 17.52%
ROIC 35.93%
Ebitda margin 29.86%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Above fair price: The current price (3198.5 β‚Ή) is higher than the fair price (740.65 β‚Ή).

Price is higher than fair: The current price (3198.5 β‚Ή) is 76.8% higher than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (33.23) is lower than that of the sector as a whole (59.64).

P/E vs Market: The company's P/E (33.23) is lower than that of the market as a whole (65.67).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (7.6) is higher than that of the sector as a whole (6.64).

P/BV vs Market: The company's P/BV (7.6) is higher than that of the market as a whole (6.56).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (6.44) is lower than that of the sector as a whole (9.32).

P/S vs Market: The company's P/S indicator (6.44) is lower than that of the market as a whole (18.88).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (21.51) is lower than that of the sector as a whole (141.59).

EV/Ebitda vs Market: The company's EV/Ebitda (21.51) is lower than that of the market as a whole (25.22).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Rising and has grown by 22.18% over the last 5 years.

Accelerating profitability: The return for the last year (38.81%) exceeds the average return for 5 years (22.18%).

Profitability vs Sector: The return for the last year (38.81%) exceeds the return for the sector (-9.37%).

5.4. ROE

ROE vs Sector: The company's ROE (23.47%) is higher than that of the sector as a whole (10.72%).

ROE vs Market: The company's ROE (23.47%) is higher than that of the market as a whole (3.38%).

5.5. ROA

ROA vs Sector: The company's ROA (17.52%) is higher than that of the sector as a whole (7.64%).

ROA vs Market: The company's ROA (17.52%) is higher than that of the market as a whole (7.93%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (35.93%) is higher than that of the sector as a whole (15.91%).

ROIC vs Market: The company's ROIC (35.93%) is higher than that of the market as a whole (15.54%).

6. Finance

6.1. Assets and debt

Debt level: (0.7606%) is quite low in relation to assets.

Increasing debt: over 5 years, the debt has increased from 0.0735% to 0.7606%.

Debt Covering: The debt is covered by 4.32% from net profit.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0.7651% is below the average for the sector '9.55%.

7.2. Stability and increase in payments

Dividend stability: The company's dividend yield 0.7651% has been steadily paid over the past 7 years, DSI=0.86.

Weak dividend growth: The company's dividend yield 0.7651% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (78.68%) are at a comfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

No insider transactions have been recorded yet

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Ajanta Pharma Limited

9.3. Comments